Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.

MuGard, Caphosol no better than standard therapy for chemo-induced oral mucositis

04 May 2020

MuGard and Caphosol do not appear to be more effective than standard topical therapy at reducing pain scores or increasing mucosal recovery in the treatment of chemotherapy-induced oral mucositis, a recent study has shown.

This study was conducted to address the limited data available regarding the treatment of established oral mucositis with oral mucoadhesive hydrogel (MuGard) or supersaturated calcium phosphate oral rinse (Caphosol) compared to standard therapies.

The authors performed a retrospective chart review involving adults treated with MuGard, Caphosol and/or standard topical therapy for established oral mucositis while admitted to a community teaching hospital. Then, they matched patients receiving newer agents (MuGard/Caphosol) to those receiving standard topical therapy (ST) using a posthoc propensity score.

Of the 147 patients included in the analysis, 14 from each group were matched. No difference in the primary endpoint of median change in average daily pain score, compared to baseline, was found between matched groups at day 3 (ST vs MuGard/Caphosol: 0 vs 0.18; p=0.830) or day 7 (0 vs 0.8; p=0.494).

There were also no between-group differences seen in opioid usage, oral mucositis symptom duration or progression, or incidence of documented infection.

“Oral mucositis, a common complication of several different anticancer therapies, causes significant morbidity in cancer patients,” the authors said. “It is characterized by the destruction of the mucosa throughout the gastrointestinal tract including the oral cavity.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.